Reactivos e instrumentos para inmunología, biología celular y biología molecular.
 
> DLin-KC2-DMA [1190197-97-7]

DLin-KC2-DMA [1190197-97-7]

Imprimir Imprimir
Por favor conéctese

Referencia HY-112758-10mg

embalaje : 10mg

Marca : MedChemExpress

Solicitar más información

Contact local distributor :


Teléfono : +1 850 650 7790

Descripciòn

DLin-KC2-DMA is an ionisable cationic lipid (pKa≈6) that is virtually non-toxic to antigen presenting cells (APCs). DLin-KC2-DMA produces significant siRNA-mediated gene silencing of GAPDH, when binds to lipid nanoparticles (LNP). DLin-KC2-DMA can be used in siRNA delivery studies[1][2].

In Vitro

DLin-KC2-DMA (1, 5 μg; 72 h) effectively produces a significant siRNA-mediated GAPDH gene silencing in both macrophages and dendritic cells[1].
DLin-KC2-DMA (24 h) exhibits high uptake into macrophages and dendritic cells[1].
DLin-KC2-DMA efficiently promotes release of encapsulated siRNA into the cytosol following uptake via the endocytotic pathway[1].
DLin-KC2-DMA displays almost no toxicity in primary APCs[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

DLin-KC2-DMA Related Antibodies

Cell Cytotoxicity Assay[1]

Cell Line: Macrophages, dendritic cells
Concentration: 5 μg/mL (DLin-KC2-DMA contained-LNPs)
Incubation Time: 72 h
Result: Displayed almost no toxicity.

Western Blot Analysis[1]

Cell Line: Macrophages, dendritic cells
Concentration: 1, 5 μg
Incubation Time: 72 h
Result: Exhibited significant GAPDH silencing of more than 60% at 1 μg and of 80% at 5 μg in macrophages.
Significantly reduced GAPDH protein and exhibited the silencing effects of 83% at 5 μg.
In Vivo

DLin-KC2-DMA contained-LNP siRNA systems (5 mg/kg; i.v.; single) effectively silences target genes in APcs in vivo[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Naive C57BL/6 mice[1].
Dosage: 3 or 5 mg/kg (DLin-KC2-DMA contained-LNPs)
Administration: Intravenous injection; single.
Result: Significantly reduced GAPDH production in peritoneal cavity macrophages and dendritic cells and in the spleen-derived APCs when at 5 mg/kg.
Peso molecular

642.09

Fòrmula

C43H79NO2
No. CAS
Appearance

Liquid (Density: 0.885±0.06 g/cm3)

Color

Colorless to light yellow

SMILES

CCCCC/C=C\C/C=C\CCCCCCCCC1(CCCCCCCC/C=C\C/C=C\CCCCC)OC(CCN(C)C)CO1
Envío

Room temperature in continental US; may vary elsewhere.
Almacenamiento

-20°C, stored under nitrogen

*The compound is unstable in solutions, freshly prepared is recommended.

Solvente y solubilidad
In Vitro: 

Ethanol : 100 mg/mL (155.74 mM; Need ultrasonic)

DMSO : 100 mg/mL (155.74 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 1.5574 mL 7.7871 mL 15.5741 mL
5 mM 0.3115 mL 1.5574 mL 3.1148 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (3.89 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.5 mg/mL (3.89 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Pureza y Documentación
Referencias

Usted podría estar interesado también en los siguientes productos:



Referencia
Descripción
Cond.
Precio Sin IVA
NB-64-06421-10mg
DLin-KC2-DMA [1190197-97-7]
 10mg 
HY-112251-10mg
D-Lin-MC3-DMA [1224606-06-7]
 10mg 
HY-112251-25mg
D-Lin-MC3-DMA [1224606-06-7]
 25mg